CANONSBURG (dpa-AFX) - Share of Mylan (MYL) continue to see considerable strength in afternoon trading on Wednesday after an early rally. After reaching a two-month intraday high, Mylan is currently up by 18.3 percent.
The jump by Mylan comes after the FDA approved two doses of the drug maker's generic version of Teva's (TEVA) Copaxone for patients with relapsing forms of multiple sclerosis.
Copyright RTT News/dpa-AFX